Shares of Ocular Therapeutix Inc. (NASDAQ:OCUL) saw unusually-high trading volume on Friday . Approximately 522,255 shares were traded during trading, a decline of 4% from the previous session’s volume of 546,577 shares.The stock last traded at $5.86 and had previously closed at $5.34.

OCUL has been the topic of several analyst reports. Morgan Stanley reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, May 12th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 price objective on shares of Ocular Therapeutix in a report on Sunday, April 10th. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “sell” rating to a “buy” rating and set a $9.25 price objective on the stock in a report on Thursday, March 17th. Finally, Cowen and Company reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Monday, June 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Ocular Therapeutix has an average rating of “Buy” and an average price target of $31.85.

The firm’s market cap is $147.11 million. The company’s 50-day moving average is $7.42 and its 200-day moving average is $8.69.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.01. The company had revenue of $458 million for the quarter. Analysts anticipate that Ocular Therapeutix Inc. will post ($1.86) EPS for the current fiscal year.

In other Ocular Therapeutix news, CEO Amarpreet Sawhney purchased 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, June 9th. The stock was acquired at an average price of $6.70 per share, with a total value of $67,000.00. Following the transaction, the chief executive officer now owns 573,733 shares in the company, valued at approximately $3,844,011.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.